Item 8.01 Other Events.

On November 1, 2008, Paul Berg, Ph.D., a member of the Board of Directors of Gilead Sciences, Inc., a Delaware corporation (the Company) and on November 26, 2008, Gregg H. Alton, Senior Vice President and General Counsel, each entered into a new stock trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934 (Rule 10b5-1). Trading under these plans will commence during the first quarter of 2009 to the extent applicable trading criteria are satisfied. James M. Denny, the lead independent director of the Company's Board of Directors, John C. Martin, PhD, Chairman, Board of Directors and Chief Executive Officer, John F. Milligan, PhD, President and Chief Operating Officer, Kevin Young, Executive Vice President, Commercial Operations, and Kristen M. Metza, Senior Vice President, Human Resources, previously established stock trading plans under Rule 10b5-1, and certain other officers and directors of the Company may do so in the future.

The information in this Form 8-K shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

---

Top of the Form